 Data suggest SINTAXTM medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis Data support development of EDP1867 for the treatment of neuroinflammatory diseases 